Founded in 2017 by Tien Lee, Aardvark Therapeutics offers a first-in-class oral composition that selectively disrupts hunger signaling and regulates energy homeostasis, providing an effective and safe treatment for obesity-related diseases. Their therapeutics do not interfere with nutrient absorption, making them a promising solution for rare genetic metabolic disorders as well.